Abstract
This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICECER) of PCV13 over PCV10. Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of (sic)11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICECER of PCV13 compared with PCV10 was below (sic)30000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below (sic)2.63 per dose.
| Original language | English |
|---|---|
| Pages (from-to) | 1841-1849 |
| Number of pages | 9 |
| Journal | Human vaccines & immunotherapeutics |
| Volume | 10 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul-2014 |
Keywords
- Cost-effectiveness
- Infant vaccination
- Netherlands
- PCV
- Pneumococcal
- Vaccines
- child
- cost effectiveness analysis
- human
- infant
- vaccination